Ryma Benayed
Overview
Explore the profile of Ryma Benayed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
8289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziegler J, Hechtman J, Rana S, Ptashkin R, Jayakumaran G, Middha S, et al.
Nat Commun
. 2025 Jan;
16(1):136.
PMID: 39746944
Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data...
2.
Spano M, Davis-Hayes C, Hameed M, Benayed R, Hwang S
Clin Imaging
. 2024 Apr;
110:110134.
PMID: 38631176
Objective: To explore pre-treatment imaging findings of neurotrophic tyrosine receptor kinase (NTRK)-rearranged spindle cell neoplasm, an emerging group of molecularly defined soft tissue tumors and summarize the clinical course, including...
3.
Krystel-Whittemore M, Petrova-Drus K, Ptashkin R, Ewalt M, Yao J, Liu Y, et al.
Haematologica
. 2024 Mar;
109(10):3269-3281.
PMID: 38450530
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients' management. In this context, unequivocally discriminating somatic from germline events is...
4.
Ptashkin R, Ewalt M, Jayakumaran G, Kiecka I, Bowman A, Yao J, et al.
Nat Commun
. 2023 Oct;
14(1):6895.
PMID: 37898613
Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor...
5.
Yang S, Gedvilaite E, Ptashkin R, Chang J, Ziegler J, Mata D, et al.
J Thorac Oncol
. 2023 Oct;
19(3):409-424.
PMID: 37838086
Introduction: Microsatellite instability (MSI) and mismatch repair (MMR) deficiency represent a distinct oncogenic process and predict response to immune checkpoint inhibitors (ICIs). The clinicopathologic features of MSI-high (MSI-H) and MMR...
6.
Franch-Exposito S, Mehine M, Ptashkin R, Bolton K, Bandlamudi C, Srinivasan P, et al.
JCO Precis Oncol
. 2023 Aug;
7:e2300070.
PMID: 37561983
Purpose: Clonal hematopoiesis (CH), the expansion of clones in the hematopoietic system, has been linked to different internal and external features such as aging, genetic ancestry, smoking, and oncologic treatment....
7.
Abramson D, Mandelker D, Brannon A, Dunkel I, Benayed R, Berger M, et al.
PLoS One
. 2023 Feb;
18(2):e0271505.
PMID: 36735656
Cell free DNA (cfDNA) and circulating tumor cell free DNA (ctDNA) from blood (plasma) are increasingly being used in oncology for diagnosis, monitoring response, identifying cancer causing mutations and detecting...
8.
Jee J, Lebow E, Yeh R, Das J, Namakydoust A, Paik P, et al.
Nat Med
. 2022 Nov;
28(11):2353-2363.
PMID: 36357680
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an...
9.
Abramson D, Mandelker D, Francis J, Dunkel I, Brannon A, Benayed R, et al.
Ophthalmol Sci
. 2022 Oct;
1(1):100015.
PMID: 36246006
Purpose: Analysis of circulating tumor DNA (ctDNA) in the plasma of patients with retinoblastoma and simulating lesions. Design: Retrospective cross-sectional study of the association of plasma ctDNA from retinoblastoma and...
10.
Giraldo N, Drill E, Satravada B, El Dika I, Brannon A, Dermawan J, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5359-5367.
PMID: 36228155
Purpose: Gallbladder carcinoma (GBC) is an uncommon and aggressive disease, which remains poorly defined at a molecular level. Here, we aimed to characterize the molecular landscape of GBC and identify...